Evidence map›Paper›PMID 42635241›Full record

ArticleBioinformatics (Oxford, England)2026

PepGen: conditional generation of peptides for MHC binding.

Dani Korpela, Alexandru Dumitrescu, Martin Stražar, Rui Li, Ramnik J Xavier, Daniel B Graham, Harri Lähdesmäki

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dani KorpelaDepartment of Computer Science, Aalto University, Espoo, 02150, Finland.ORCID 0000-0002-2845-8836
Alexandru DumitrescuDepartment of Computer Science, Aalto University, Espoo, 02150, Finland.ORCID 0000-0003-0909-9484
Martin StražarBroad Institute of MIT and Harvard, Cambridge, MA, 02142, United States.ORCID 0000-0003-3064-1055
Rui LiBroad Institute of MIT and Harvard, Cambridge, MA, 02142, United States.ORCID 0000-0002-4803-5339
Ramnik J XavierBroad Institute of MIT and Harvard, Cambridge, MA, 02142, United States.ORCID 0000-0002-5630-5167
Daniel B GrahamBroad Institute of MIT and Harvard, Cambridge, MA, 02142, United States.ORCID 0000-0002-8403-8115
Harri LähdesmäkiDepartment of Computer Science, Aalto University, Espoo, 02150, Finland.

Funding

Cancer Foundation of FinlandJuhani Aho Medical FoundationResearch Council of Finland 359135Sigrid Jusélius FoundationSwedish Academy of Engineering Sciences in Finland
6 · The paper itself

Abstract

motivationPeptide-MHC II binding drives adaptive immunity, yet discovery of novel binder peptides remains challenging due to open binding grooves of MHC-II that accommodate variable-length peptides. While discriminative models perform well, they are unfeasible for generation via enumeration due to vast peptide space (2013≈8×1016 for peptides of length 13 amino acids). Generative AI approaches could accelerate binder design to enable vaccines targeted to particular MHC-II alleles or optimize other peptide chemical properties.

resultsWe introduce PepGen, the first protein language model for MHC II peptide generation building on Generalized Language Modeling. PepGen conditions on alleles, arbitrary partial peptides including putative TCR-interacting motifs, and continuous binding affinity. Across multiple benchmarks including infilling and de novo generation, PepGen outperformed frequency sampling, Gibbs clustering, and autoregressive baselines. Adjusted log-probabilities enable good classification performance. Experimental validation confirmed that the SARS-CoV-2 peptide TEGALNTPKDHIGTR binding the HLA-DQA101:03-DQB106:03 allele can be redesigned to bind the HLA-DQA101:02-DQB105:02 allele. PepGen generated three putative TCR-motif-preserving binders gaining up to 70% of original MFI. Overall, PepGen provides scalable, motif-constrained MHC II peptide redesign and de novo generation, validated through thorough benchmarks and functional assays. AVAILABILITY AND IMPLEMENTATION: Code and Data are available at https://github.com/DaniTheOrange/PepGen.

Indexed as

Histocompatibility Antigens Class IIPeptidesSoftwareAllelesGenerative Artificial IntelligenceHumansImmunoinformaticsProtein BindingSARS-CoV-2Histocompatibility Antigens Class IIPeptides

Identifiers

PMID42635241
PMCPMC13501301

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.